专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10813959B2 Cancer therapy with a parvovirus combined with bevacizumab 有权
公开(公告)号：US10813959B2
公开(公告)日：2020-10-27
申请号：US15550354
申请日：2016-02-10
申请人： Deutsches Krebsforschungszentrum , Ruprecht-Karls-Universität Heidelberg
发明人： Karsten Geletneky , Jean Rommelaere , Wolfgang Wick , Antje Wick , Michael Dahm
IPC分类号： A61K35/768 , C07K16/22 , A61K39/395 , A61K9/00
摘要： Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.

2. 发明申请

US20180221479A1 AGENTS FOR USE IN THE TREATMENT OF GLIOMA 审中-公开
公开(公告)号：US20180221479A1
公开(公告)日：2018-08-09
申请号：US15748537
申请日：2016-07-06
申请人： RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG , DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： Matthias Osswald , Wolfgang Wick , Frank Winkler , Erik Jung , Jonas Blaes
IPC分类号： A61K39/395 , A61K31/522 , A61P35/00
摘要： The present invention relates to agents for use in the treatment of glioma, in particular astrocytoma WHO IF and 111°, as well as IV0 (glioblastoma), in a subject.

3. 发明申请

US20150023991A1 MEANS AND METHODS FOR TREATING OR DIAGNOSING IDH1 R132H MUTANT-POSITIVE CANCERS 审中-公开
标题翻译：治疗或诊断IDH1 R132H突变型癌的手段和方法
公开(公告)号：US20150023991A1
公开(公告)日：2015-01-22
申请号：US14370224
申请日：2013-01-03
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM , RUPRECHT-KARLS-UNIVERISTAT
发明人： Michael Platten , Theresa Schumacher , Wolfgang Wick
IPC分类号： G01N33/574 , C12N9/04
CPC分类号： G01N33/57496 , A61K38/43 , A61K39/0011 , C12N9/0006 , C12Y101/01042 , G01N33/57407 , G01N33/57426 , G01N2333/904
摘要： The present invention concerns the field of tumor therapeutics and diagnostics. Specifically, it relates to a peptide comprising at least 8 amino acids in length which are present as contiguous amino acid sequence in the human Isocitratdehydrogenase Type 1 (IDH1), wherein said peptide has at least one amino acid exchange from R to H at a position corresponding to position 132, for use in preventing and/or treating cancer. Further contemplated is a medicament comprising the said peptide. Furthermore, the invention relates to a method for diagnosing cancer characterized by having a mutation in the genome of at least some cancer cells which results in the expression of a mutant IDH1 having the R132H mutation comprising the steps of contacting a blood sample of a subject suspected to suffer from such a cancer with a peptide comprising at least 10 amino acids in length which are present as contiguous amino acid sequence in the IDH1, wherein said peptide has at least one amino acid exchange from R to H at a position corresponding to position 132 for a time and under conditions which allow for specific binding of a component of the immune system to the peptide, and determining whether, or not, binding of the said component of the immune system to the peptide occurred, wherein the cancer is diagnosed if the occurrence of binding has been determined. Provided by the invention is also a kit and a device for carrying out said method.
摘要翻译：本发明涉及肿瘤治疗和诊断领域。具体地说，本发明涉及一种包含长度为至少8个氨基酸的肽，其在人类异柠檬酸脱氢酶1型（IDH1）中作为连续氨基酸序列存在，其中所述肽在位置上具有至少一个R至H的氨基酸交换对应于位置132，用于预防和/或治疗癌症。进一步考虑的是包含所述肽的药物。此外，本发明涉及一种用于诊断癌症的方法，其特征在于在至少一些癌细胞的基因组中具有导致具有R132H突变的突变体IDH1的表达的突变，包括以下步骤：使被怀疑的受试者的血液样品患有长度为至少10个氨基酸的肽的这种癌症，其以IDH1中的连续氨基酸序列存在，其中所述肽在对应于位置132的位置具有至少一个R至H的氨基酸交换在一段时间和在允许免疫系统的组分与肽的特异性结合的条件下，以及确定是否发生免疫系统的所述组分与肽的结合，其中诊断出癌症是否已经确定了结合的发生。本发明还提供了一种用于执行所述方法的套件和装置。

4. 发明申请

US20210060102A1 CANCER THERAPY WITH A PARVOVIRUS COMBINED WITH BEVACIZUMAB 有权
公开(公告)号：US20210060102A1
公开(公告)日：2021-03-04
申请号：US16949331
申请日：2020-10-26
申请人： Deutsches Krebsforschungszentrum , RUPRECHT-KARLS-UNIVERSITÄT
发明人： Karsten Geletneky , Jean Rommelaere , Wolfgang Wick , Antje Wick , Michael Dahm
IPC分类号： A61K35/768 , A61K39/395 , C07K16/22 , A61K9/00
摘要： Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.

5. 发明申请

US20190117768A1 CANCER THERAPY WITH AN ONCOLYTIC VIRUS COMBINED WITH A CHECKPOINT INHIBITOR 审中-公开
公开(公告)号：US20190117768A1
公开(公告)日：2019-04-25
申请号：US16148257
申请日：2018-10-01
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM , RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
发明人： Barbara Leuchs , Antonio Marchini , Jean Rommelaere , Assia Angelova , Dirk Jager , Wolfgang Wick , Michael Dahm
IPC分类号： A61K39/395 , A61K45/06 , A61P35/00 , A61K35/768 , C07K16/28
摘要： The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

6. 发明授权

US11767352B2 Histone anti-cancer vaccines 有权
公开(公告)号：US11767352B2
公开(公告)日：2023-09-26
申请号：US16832465
申请日：2020-03-27
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM
发明人： Michael Platten , Theresa Bunse , Wolfgang Wick , Katharina Ochs , Martina Ott , Lukas Bunse
IPC分类号： A61K38/16 , A61K38/00 , A61P35/00 , C07K14/47 , A61K39/00 , C07K14/725 , G01N33/574
CPC分类号： C07K14/47 , A61K38/16 , A61K39/0011 , A61P35/00 , C07K14/4748 , C07K14/7051 , G01N33/57496 , A61K38/00 , A61K2039/5158 , C07K2319/00 , G01N2333/47
摘要： The present invention pertains to novel immunogenic peptide sequences that can be used as vaccines in the treatment of cancer diseases such as brain cancers and specifically glioma. The cancer vaccines of the invention are designed based on the K27M mutated variant of the human Histone 3. Provided are further fusion proteins comprising the sequences of the cancer vaccines, nucleic acids encoding such vaccines, such as RNA vaccines, and vectors and host cells comprising these sequences. Furthermore the invention pertains to T cells and T cell receptors binding the cancer vaccines of the invention, preferably when presented by the human Major Histocompatibility Complex (MHC). The peptide immunogens of the invention elicit a HLA restricted immune response and therefore are of use in the treatment of cancer diseases, in particular glioma. Further aspects of the invention pertain to pharmaceutical compositions as well as diagnostic methods based on the immunogenic capacity of the disclosed peptides.

7. 发明申请

US20210228714A1 CANCER THERAPY WITH AN ONCOLYTIC VIRUS COMBINED WITH A CHECKPOINT INHIBITOR 有权
公开(公告)号：US20210228714A1
公开(公告)日：2021-07-29
申请号：US17226199
申请日：2021-04-09
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM , RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
发明人： Barbara Leuchs , Antonio Marchini , Jean Rommelaere , Assia Angelova , Dirk Jager , Wolfgang Wick , Michael Dahm
IPC分类号： A61K39/395 , A61K35/768 , C07K16/28 , A61K45/06 , A61P35/00
摘要： The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

8. 发明授权

US11027013B2 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor 有权
公开(公告)号：US11027013B2
公开(公告)日：2021-06-08
申请号：US16148257
申请日：2018-10-01
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM , RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
发明人： Barbara Leuchs , Antonio Marchini , Jean Rommelaere , Assia Angelova , Dirk Jager , Wolfgang Wick , Michael Dahm
IPC分类号： A61K35/768 , A61P35/00 , A61K45/06 , A61K39/395 , C07K16/28 , A61K39/00
摘要： The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

9. 发明授权

US10161940B2 Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers 有权
公开(公告)号：US10161940B2
公开(公告)日：2018-12-25
申请号：US14370224
申请日：2013-01-03
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM , RUPRECHT-KARLS-UNIVERSITÄT
发明人： Michael Platten , Theresa Bunse , Wolfgang Wick
IPC分类号： G01N33/00 , A61K38/43 , G01N33/574 , C12N9/04 , A61K39/00
摘要： The present invention concerns the field of tumor therapeutics and diagnostics. Specifically, it relates to a peptide comprising at least 8 amino acids in length which are present as contiguous amino acid sequence in the human Isocitratdehydrogenase Type 1 (IDH1), wherein said peptide has at least one amino acid exchange from R to H at a position corresponding to position 132, for use in preventing and/or treating cancer. Further contemplated is a medicament comprising the said peptide. Furthermore, the invention relates to a method for diagnosing cancer characterized by having a mutation in the genome of at least some cancer cells which results in the expression of a mutant IDH1 having the R132H mutation comprising the steps of contacting a blood sample of a subject suspected to suffer from such a cancer with a peptide comprising at least 10 amino acids in length which are present as contiguous amino acid sequence in the IDH1, wherein said peptide has at least one amino acid exchange from R to H at a position corresponding to position 132 for a time and under conditions which allow for specific binding of a component of the immune system to the peptide, and determining whether, or not, binding of the said component of the immune system to the peptide occurred, wherein the cancer is diagnosed if the occurrence of binding has been determined. Provided by the invention is also a kit and a device for carrying out said method.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式